User:Mr. Ibrahem/Ustekinumab

Ustekinumab, sold under the brand name Stelara, is a medication used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. It is generally only used if other treatments have not been effective. It is given by intravenous infusion or subcutaneous injection.

Common side effects include joint pain, back pain, diarrhea, and infections. Other side effects may include anaphylaxis, cancer, and reversible posterior leukoencephalopathy syndrome. It is a monoclonal antibody that targets IL-12 and IL-23. It is classified as a disease-modifying antirheumatic drug (DMARD).

Ustekinumab was approved for medical use in Europe and the United States in 2009. In the United Kingdom the 45 mg and 90 mg doses cost the NHS £2,150 each as of 2021. In the United States it is about 12,500 USD per 45 mg.